Seasonal influenza vaccine uptake among Chinese in Hong Kong: barriers, enablers and vaccination rates.
Barriers
Chinese
enablers
seasonal influenza
vaccination rate
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
02 07 2020
02 07 2020
Historique:
pubmed:
25
1
2020
medline:
22
6
2021
entrez:
25
1
2020
Statut:
ppublish
Résumé
Low influenza vaccination rates were observed in Asian countries including China. This study investigated the updated seasonal influenza vaccination rates among Chinese in Hong Kong, and the barriers and enablers to vaccination. Eight focus groups were conducted among the Chinese general public, followed by a telephone survey between March and April 2018 with 2,452 respondents (response rate 41.4%). Of the survey respondents, 29.1% had received influenza vaccine in the past 12 months. A majority of them agreed with 'enhancing immunity' (94.4%) and 'feeling safer' (92.3%) as their reasons for vaccination, followed by the belief on 'quicker recovery' if they had influenza (69.5%), and free/subsidized vaccine (53.8%). Among respondents who had not received influenza vaccine, 71.2% 'believed in the strength of their own immunity' and 65.6% perceived 'low-risk of getting influenza'. Less than half were 'worried about side-effects' and 'effectiveness'. The groups aged 65-74 and 75 or above had vaccination rates of 49.1% and 69.9%, respectively, in contrast to 13.9% for the group aged 18-64. A rate of 37.9% for children was reported by the 442 respondents having children. The high uptake of vaccines among the children and elderly suggests the positive impact of the subsidy and outreach programs. However, young and middle-aged adults tend to believe in the strength of their own immunity and underestimate the infection risk. Public education should emphasize that inactivated vaccines such as influenza vaccines work by means of the viral antigens stimulating the host's immune system toward the major types of seasonal influenza.
Sections du résumé
BACKGROUND
Low influenza vaccination rates were observed in Asian countries including China. This study investigated the updated seasonal influenza vaccination rates among Chinese in Hong Kong, and the barriers and enablers to vaccination.
METHODS
Eight focus groups were conducted among the Chinese general public, followed by a telephone survey between March and April 2018 with 2,452 respondents (response rate 41.4%).
RESULTS
Of the survey respondents, 29.1% had received influenza vaccine in the past 12 months. A majority of them agreed with 'enhancing immunity' (94.4%) and 'feeling safer' (92.3%) as their reasons for vaccination, followed by the belief on 'quicker recovery' if they had influenza (69.5%), and free/subsidized vaccine (53.8%). Among respondents who had not received influenza vaccine, 71.2% 'believed in the strength of their own immunity' and 65.6% perceived 'low-risk of getting influenza'. Less than half were 'worried about side-effects' and 'effectiveness'. The groups aged 65-74 and 75 or above had vaccination rates of 49.1% and 69.9%, respectively, in contrast to 13.9% for the group aged 18-64. A rate of 37.9% for children was reported by the 442 respondents having children.
CONCLUSIONS
The high uptake of vaccines among the children and elderly suggests the positive impact of the subsidy and outreach programs. However, young and middle-aged adults tend to believe in the strength of their own immunity and underestimate the infection risk. Public education should emphasize that inactivated vaccines such as influenza vaccines work by means of the viral antigens stimulating the host's immune system toward the major types of seasonal influenza.
Identifiants
pubmed: 31977275
doi: 10.1080/21645515.2019.1709351
pmc: PMC7482890
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1675-1684Références
Public Health. 2012 Dec;126(12):1007-12
pubmed: 23141148
Hum Vaccin Immunother. 2019;15(1):97-101
pubmed: 30148689
Vaccine. 2015 Sep 11;33(38):4737-40
pubmed: 26226564
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
BMC Infect Dis. 2014 Dec 11;14:670
pubmed: 25495228
Bull World Health Organ. 2012 Apr 1;90(4):279-288B
pubmed: 22511824
Hum Vaccin Immunother. 2018;14(11):2715-2721
pubmed: 29995561
Clin Infect Dis. 2018 May 2;66(10):1511-1518
pubmed: 29206909
PLoS One. 2013 Jul 19;8(7):e68019
pubmed: 23894292
BMC Infect Dis. 2015 Feb 18;15:72
pubmed: 25886607
Med J Aust. 2010 Jan 4;192(1):33-6
pubmed: 20047546
BMC Public Health. 2013 Jul 12;13:647
pubmed: 23849209
Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76
pubmed: 23210147
Epidemiol Infect. 2017 Dec;145(16):3334-3344
pubmed: 29117874
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
PLoS One. 2013 Sep 09;8(9):e73724
pubmed: 24040041
Vaccine. 2018 May 31;36(23):3315-3322
pubmed: 29706294
Vaccine. 2011 Oct 13;29(44):7599-601
pubmed: 21827812
MMWR Recomm Rep. 2018 Aug 24;67(3):1-20
pubmed: 30141464
Gerontologist. 2018 Nov 20;:
pubmed: 30462212
Epidemiol Infect. 2013 Feb;141(2):377-89
pubmed: 22717154
Vaccine. 2015 Jun 4;33(24):2741-56
pubmed: 25936726
Am J Infect Control. 2012 Sep;40(7):e225-7
pubmed: 22743046